Real-World Analysis of Afatinib for EGFR-Mutated Lung Adenocarcinoma Under Universal Health Coverage: A Single Center Experience

Abstract

Background: Afatinib, an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), has now become standard targeted therapy for EGFR-mutated lung adenocarcinoma patients in Indonesia, and approved under universal health coverage scheme in Indonesia. Objectives: This study aimed to evaluate the outcomes and efficacy of afatinib therapy in lung adenocarcinoma patients with EGFR mutations at Persahabatan General Hospital, a tertiary referral respiratory hospital, under universal health coverage scheme. Methods: This retrospective cohort study was conducted based on medical records of EGFR-mutated lung adenocarcinoma patients who received afatinib at Thoracic Oncology Outpatient Clinic Persahabatan Hospital, between January 2018 and December 2021. All patients initially received afatinib at a dose of 40 mg dose, with some had dose reduction to 20 or 30 mg. Survival analysis was conducted using Kaplan-Meier and Log-Rank Test. Results: Among 86 participants, 78% were diagnosed with stage IVA disease at the initiation of afatinib therapy. Exon 19 deletion were observed in over 50% of patients, and pleural metastases were present in nearly 60%. The median progression-free survival (PFS) was 13 months (95% CI: 10.5 - 15.5), and the median overall survival (OS) was 17 months (95% CI: 14.9 -19.1). The one-year survival rate was 65.1%. Dose reduction occurred in 43% of participants, with no significant differences in survival outcomes. Median PFS was 15 months (95% CI: 12.4 - 17.6) with dose reduction and 12 months (95% CI: 8.1 - 15.9) without (P = 0.85). Median OS was 17 months (95% CI: 14.9 - 19.1) with dose reduction and 19 months (95% CI: 13.7 - 24.3) without (P = 0.59). Conclusions: Afatinib has comparable efficacy for EGFR-mutated lung adenocarcinoma patients and dose adjustment did not affect the survival rate, in patient under universal health coverage program in Indonesia.

Description

Keywords

Citation

URI

Endorsement

Review

Supplemented By

Referenced By